miR-23a blockade enhances adoptive T cell transfer therapy by preserving immunecompetence in the tumor microenvironment

OncoImmunology

Volumn 4, Issue 3, 2015, Pages 1-3

  Lin, Regina ^a   Sampson, John H ^a   Li, Qi Jing ^a   Zhu, Bo ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer immunotherapy; Cytotoxic CD8+ T lymphocytes; Immune evasion; microRNA; TGF

Indexed keywords

MICRORNA; MICRORNA 23A; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; PROTEIN EXPRESSION; T CELL TRANSFER THERAPY; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

EID: 84954534927     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.990803     Document Type: Article

References (10)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380-4; PMID:11357146; http://dx.doi.org/10.1038/35077246
2. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol 2011; 29:550-7; PMID:21663987; http://dx.doi.org/10.1016/j.tibtech.2011.04.009
3. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 2014; 20:4262-73; PMID:24919573; http://dx.doi.org/10.1158/1078-0432.CCR-13-2627
4. Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137:1005-17; PMID:19524505; http://dx.doi.org/10.1016/j.cell.2009.04.021
5. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011; 43:371-8; PMID:21423181; http://dx.doi.org/10.1038/ng.786
6. Kallies A, Xin A, Belz GT, Nutt SL. Blimp-1 transcription factor is required for the differentiation of effector CD8(C) T cells and memory responses. Immunity 2009; 31:283-95; PMID:19664942; http://dx.doi.org/10.1016/j.immuni.2009.06.021
7. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985; 316:701-5; PMID:3861940; http://dx.doi.org/10.1038/316701a0
8. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005; 8:369-80; PMID:16286245; http://dx.doi.org/10.1016/j.ccr.2005.10.012
9. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4:721-6; PMID:17694064; http://dx.doi.org/10.1038/nmeth1079
10. Lin R, Chen L, Chen G, Hu C, Jiang S, Sevilla J, Wan Y, Sampson JH, Zhu B, Li QJ. Targeting miR-23a in CD8C cytotoxic T lymphocytes prevents tumordependent immunosuppression. J Clin Investigat 2014; 124:5352-67; PMID:25347474; http://dx.doi.org/10.1172/JCI76561